Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Unknown 1

Sponsor Class

OTHER 10INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 4Gastrointestinal 3Other solid neoplasm 1Other neoplasm 1Lymphoid 1

Conditions

Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Advanced Pancreatic Cancer 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 215Irinotecan 185Cisplatin 142Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 55Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 40trifluridine tipiracil drug combination 38lenvatinib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × penpulimab × Gastrointestinal × Clear all
NCT06821503 2026-03-10

Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Recruiting
72 enrolled
Gastrointestinal

Advanced Pancreatic Cancer

NCT06010901 2024-01-23

A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Unknown
75 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT05862337 2023-05-17

Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Recruiting
480 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡